184 related articles for article (PubMed ID: 21264531)
1. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray.
Liu D; He J; Yuan Z; Wang S; Peng R; Shi Y; Teng X; Qin T
Med Oncol; 2012 Jun; 29(2):401-5. PubMed ID: 21264531
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.
He J; Peng R; Yuan Z; Wang S; Peng J; Lin G; Jiang X; Qin T
Med Oncol; 2012 Jun; 29(2):406-10. PubMed ID: 21264529
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
5. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
[TBL] [Abstract][Full Text] [Related]
6. Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer.
Wu MQ; Hu P; Gao J; Wei WD; Xiao XS; Tang HL; Li X; Ge QD; Jia WH; Liu RB; Xie XM
Asian Pac J Cancer Prev; 2013; 14(1):287-92. PubMed ID: 23534739
[TBL] [Abstract][Full Text] [Related]
7. Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer.
Kim S; Jung WH; Koo JS
Tumour Biol; 2012 Oct; 33(5):1681-94. PubMed ID: 22638807
[TBL] [Abstract][Full Text] [Related]
8. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
9. Metabolic phenotypes in triple-negative breast cancer.
Kim S; Kim DH; Jung WH; Koo JS
Tumour Biol; 2013 Jun; 34(3):1699-712. PubMed ID: 23443971
[TBL] [Abstract][Full Text] [Related]
10. Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients.
Liu L; Liu Z; Qu S; Zheng Z; Liu Y; Xie X; Song F
Diagn Pathol; 2013 May; 8():71. PubMed ID: 23635316
[TBL] [Abstract][Full Text] [Related]
11. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
Montagna E; Maisonneuve P; Rotmensz N; Cancello G; Iorfida M; Balduzzi A; Galimberti V; Veronesi P; Luini A; Pruneri G; Bottiglieri L; Mastropasqua MG; Goldhirsch A; Viale G; Colleoni M
Clin Breast Cancer; 2013 Feb; 13(1):31-9. PubMed ID: 23098574
[TBL] [Abstract][Full Text] [Related]
13. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
14. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
15. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
[TBL] [Abstract][Full Text] [Related]
16. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negative breast cancer.
He JH; Luo RZ; Cai MY; Li M; Lu JB; Yuan ZY
Med Oncol; 2013 Mar; 30(1):468. PubMed ID: 23345115
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?
Demir L; Yigit S; Sadullahoglu C; Akyol M; Cokmert S; Kucukzeybek Y; Alacacioglu A; Cakalagaoglu F; Tarhan MO
Asian Pac J Cancer Prev; 2014; 15(22):9739-45. PubMed ID: 25520097
[TBL] [Abstract][Full Text] [Related]
19. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer.
Wu M; Wei W; Xiao X; Guo J; Xie X; Li L; Kong Y; Lv N; Jia W; Zhang Y; Xie X
Med Oncol; 2012 Dec; 29(5):3240-9. PubMed ID: 22661383
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
